ClinicalTrials.gg
Status unknownNCT02985255Updated Dec 7, 2016

Role of Neo-adjuvant Chemotherapy in Tongue Preservation in Locally Advanced Squamous Cell Carcinoma of Oral Tongue

A Phase 2 interventional study of Docetaxel and Cisplatin in Tongue Neoplasms, Squamous Cell Carcinoma and Anterior Tongue Squamous Cell Carcinoma, sponsored by HealthCare Global Enterprise Ltd.. Status unknown at 1 site in India. Open to participants aged 1 Year to 99 Years. Per ClinicalTrials.gov, last updated 2016-12-07.

Sponsored by HealthCare Global Enterprise Ltd. · Phase 2, Interventional, and Treatment

The sponsor has not verified this record recently (last verified Dec 2016), so the status shown — last known as Recruiting — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
30
Allocation
Not applicable
Ages
1 Year to 99 Years
Sex
All
01

Study summary

Patients enrolled for the study, who are eligible for NACT, will undergo a pre-treatment workup comprising of Evaluation Under Anesthesia (EUA) for tumor Mapping and tissue biopsy along with a PET-CT scan. Subsequently, they would undergo 3 cycles of NACT (weekly thrice) with DCF. They would be reassessed with PET-CT and EUA +/- biopsy after the end of the third cycle. Those who are achieving CR would undergo adjuvant CTRT. Subjects who have a PR in the PET-CT scan will be re-classified based on the biopsy report. If they remain in the PR group they will undergo surgery but if the biopsy in is negative for malignancy, they will undergo adjuvant CTRT. Those subjects with SD or PD would undergo surgery. Subsequently, further radiation and/ or chemotherapy will be decided based on the final histopathology (of the surgical specimen) reports.

PET-CT and EUA +/- HPE analyses would be repeated on follow-up after 3 months of treatment completion.

Read the detailed description

Patients enrolled for the study, who are eligible for Neoadjuvant chemotherapy, will undergo a pre-treatment workup comprising of Evaluation Under Anesthesia (EUA) for tumor Mapping and tissue biopsy along with a PET-CT scan. Subsequently, they would undergo 3 cycles of Neoadjuvant chemotherapy (weekly thrice) with injection Docetaxel, Cisplatin, and 5-FU. They would be reassessed with PET-CT and EUA +/- biopsy after the end of the third cycle. Those who are achieving a Complete Response (CR) would undergo adjuvant chemo-radiotherapy. Subjects who have a partial response (PR) in the PET-CT scan will be re-classified based on the biopsy report. If they remain in the PR group they will undergo surgery. If the biopsy in these patients is negative for malignancy, they will undergo adjuvant chemoradiotherapy. Those subjects with stable disease (SD) or progressive disease (PD) would undergo surgery. Subsequently, further radiation and/ or chemotherapy will be decided based on the final histopathology (of the surgical specimen) reports.

PET-CT and EUA +/- HPE analyses would be repeated on follow-up after 3 months of treatment completion.

02

Conditions studied

  • Tongue Neoplasms
  • Squamous Cell Carcinoma
  • Anterior Tongue Squamous Cell Carcinoma

Keywords

  • Neoadjuvant Chemotherapy
  • Tongue Malignancy
  • Squamous Cell Carcinoma
03

In context

Tongue Neoplasms

121 studies on the registry are indexed under Tongue Neoplasms; 12 are open to participants now.

This study's planned enrollment of 30 is below the median of 42 across 93 interventional studies indexed under Tongue Neoplasms.

Browse Tongue Neoplasms studies →

Lead sponsor

HealthCare Global Enterprise Ltd. is the lead sponsor of 3 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
1 Year to 99 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients of newly diagnosed squamous cell carcinoma (well/ moderately/ poorly differentiated) of oral tongue (anterior two third) presenting to Health Care Global Enterprises Ltd between January 2016 to March 2017 will be included in the study.
  • Stage III and stage IV (T3, 4 N0-3, M 0) and selected cases of T2 with advanced nodal status will also be included in the study.

Exclusion criteria

Exclusion Criteria:

  • Patients having recurrence/ residual disease of oral tongue.
  • Patients who have received alternative treatments before being evaluated for NACT
  • Patient who are not fit for NACT
  • Patient not able to give consent
05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
30 participants (estimated)

Study arms

  • Experimental
    Neoadjuvant Arm

    Study Subjects, eligible for NACT would undergo a pretreatment workup with Evaluation Under Anesthesia for tumor Mapping and tissue biopsy along with a PET-CT scan. They would undergo 3 cycles of NACT (weekly thrice) with injection Docetaxel, Cisplatin and 5-FU after which reassessment with PET-CT and EUA +/- biopsy would be done. Those achieving CR would undergo adjuvant CTRT while subjects with PR in PET-CT scan will be reclassified based on the biopsy report. If biopsy is negative for malignancy, they will undergo adjuvant CTRT but would undergo surgery if in the PR group. Subjects with SD or PD would undergo surgery. PET-CT and EUA +/- HPE analyses would be repeated on follow-up after 3 months of treatment completion.

    Drug: Docetaxel · Drug: Cisplatin · Drug: 5FU · Radiation: Radiotherapy · Procedure: Glossectomy

Interventions

  • Neoadjuvant Arm

  • Neoadjuvant Arm

  • Drug5FU

    Neoadjuvant Arm

  • RadiationRadiotherapy

    Neoadjuvant Arm

  • ProcedureGlossectomy

    Neoadjuvant Arm

06

What researchers measure

Primary outcomes

  1. Tongue Preservation Rate

    A ratio of the number of study subjects who have achieved a complete response and do not require surgery, after 3 cycles of NaCT to the total number of subjects recruited to the study.

    Time frame: At Response evaluation post 3rd CT Cycle (approximately 7 months post recruitment)

Secondary outcomes

  1. Overall Survival

    Overall Survival Rate (Date of diagnosis to date of death or last follow-up) in different sub-cohorts of the study

    Time frame: 2 years post treatment completion

  2. Progression Free Survival

    Progression Free Survival Rate (Primary treatment end date to date of progression or last follow-up) in difference sub-cohorts of the study

    Time frame: 2 years post treatment completion

  3. Sensitivity and Specificity of PET-CT

    Ability of PETCT (along with HPE and EUA) to detect response rates in study subjects undergoing NACT for Ca Tongue

    Time frame: At Baseline and after 12-15 weeks (post 3 cycles of NaCT (Typically 3 weeks))

07

Study locations

1 of 1 sites recruiting
  • HealthCare Global Enterprises Ltd
    Bangalore, Karnataka 560027, India
    Recruiting
    • Vishal US Rao, MS · Contactdrvishalrao@yahoo.com · 00919739774949
    • Sataksi Chatterjee, MS · Contactsataksis2007@gmail.com · 00918971966903
    • Shekhar Patil, DM · Sub investigator
    • Radheshyam Naik, DM · Sub investigator
    • Vijay Agarwal, Phd · Sub investigator
    • Ajai BS Kumar, MS · Sub investigator
    • Kumara Swamy, MD · Sub investigator
    • Vikram Maiya, MD · Sub investigator
    • Ravi Nayar, MS · Sub investigator
    • Sataksi Chaterjee, MS · Sub investigator
    • Raghavendra M Rao, PhD · Sub investigator
    • Amritanshu Ram, PhD · Sub investigator
08

References and documents

Publications

  • Barringer DA, Hutcheson KA, Sturgis EM, Kies MS, Lewin JS. Effect of induction chemotherapy on speech and swallowing function in patients with oral tongue cancer. Head Neck. 2009 May;31(5):611-7. doi: 10.1002/hed.20989. PubMed 19107949 ↗
  • Kies MS, Boatright DH, Li G, Blumenschein G, El-Naggar AK, Brandon Gunn G, Lewin JS, Steinhaus GD, Sturgis EM. Phase II trial of induction chemotherapy followed by surgery for squamous cell carcinoma of the oral tongue in young adults. Head Neck. 2012 Sep;34(9):1255-62. doi: 10.1002/hed.21906. Epub 2011 Oct 19. PubMed 22009800 ↗
  • Pignon JP, le Maitre A, Maillard E, Bourhis J; MACH-NC Collaborative Group. Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): an update on 93 randomised trials and 17,346 patients. Radiother Oncol. 2009 Jul;92(1):4-14. doi: 10.1016/j.radonc.2009.04.014. Epub 2009 May 14. PubMed 19446902 ↗
  • Blanchard P, Bourhis J, Lacas B, Posner MR, Vermorken JB, Cruz Hernandez JJ, Bourredjem A, Calais G, Paccagnella A, Hitt R, Pignon JP; Meta-Analysis of Chemotherapy in Head and Neck Cancer, Induction Project, Collaborative Group. Taxane-cisplatin-fluorouracil as induction chemotherapy in locally advanced head and neck cancers: an individual patient data meta-analysis of the meta-analysis of chemotherapy in head and neck cancer group. J Clin Oncol. 2013 Aug 10;31(23):2854-60. doi: 10.1200/JCO.2012.47.7802. Epub 2013 Jul 8. PubMed 23835714 ↗
  • Forastiere AA, Zhang Q, Weber RS, Maor MH, Goepfert H, Pajak TF, Morrison W, Glisson B, Trotti A, Ridge JA, Thorstad W, Wagner H, Ensley JF, Cooper JS. Long-term results of RTOG 91-11: a comparison of three nonsurgical treatment strategies to preserve the larynx in patients with locally advanced larynx cancer. J Clin Oncol. 2013 Mar 1;31(7):845-52. doi: 10.1200/JCO.2012.43.6097. Epub 2012 Nov 26. PubMed 23182993 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Apr 2016, a primary completion of Jun 2017 and a completion of Jun 2017. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 29, 2016
First posted
Dec 7, 2016
Start
Apr 2016
Primary completionEst.
Jun 2017
CompletionEst.
Jun 2017
Last update
Dec 7, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 7, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02985255
Lead sponsor
HealthCare Global Enterprise Ltd.
Responsible party
Vishal U S Rao (Senior Consultant, HealthCare Global Enterprise Ltd.) — Principal investigator
First posted
Dec 7, 2016
Start date
Apr 2016
Primary completion
Jun 2017 (estimated)
Completion
Jun 2017 (estimated)
Last update
Dec 7, 2016

Study contacts

Vishal US Rao, MS
Contact
drvishalrao@yahoo.com
00919739774949
Sataksi Chatterjee, MS
Contact
sataksis2007@gmail.com
00918971966903
Vishal US Rao, MS
principal investigator · Dept of Head & Neck Surgery, HealthCare Global Enterprises Ltd.

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Dec 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Docetaxel · Cisplatin · Fluorouracil

Start the discussion